BR112016010166A2 - métodos para usar interleucina-10 para tratar doenças e distúrbios - Google Patents
métodos para usar interleucina-10 para tratar doenças e distúrbiosInfo
- Publication number
- BR112016010166A2 BR112016010166A2 BR112016010166A BR112016010166A BR112016010166A2 BR 112016010166 A2 BR112016010166 A2 BR 112016010166A2 BR 112016010166 A BR112016010166 A BR 112016010166A BR 112016010166 A BR112016010166 A BR 112016010166A BR 112016010166 A2 BR112016010166 A2 BR 112016010166A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- disorders
- interleukin
- treat diseases
- diseases
- Prior art date
Links
- 102000003814 Interleukin-10 Human genes 0.000 title 1
- 108090000174 Interleukin-10 Proteins 0.000 title 1
- 208000037765 diseases and disorders Diseases 0.000 title 1
- 229940076144 interleukin-10 Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000028709 inflammatory response Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361902702P | 2013-11-11 | 2013-11-11 | |
| PCT/US2014/064620 WO2015070060A1 (en) | 2013-11-11 | 2014-11-07 | Methods of using interleukin-10 for treating diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016010166A2 true BR112016010166A2 (pt) | 2017-12-05 |
Family
ID=53042151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016010166A BR112016010166A2 (pt) | 2013-11-11 | 2014-11-07 | métodos para usar interleucina-10 para tratar doenças e distúrbios |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11413332B2 (enExample) |
| EP (1) | EP3068425B1 (enExample) |
| JP (1) | JP6660297B2 (enExample) |
| KR (1) | KR20160079114A (enExample) |
| CN (2) | CN105848674A (enExample) |
| AU (1) | AU2014346537A1 (enExample) |
| BR (1) | BR112016010166A2 (enExample) |
| CA (1) | CA2928710A1 (enExample) |
| ES (1) | ES2862139T3 (enExample) |
| IL (1) | IL245303A0 (enExample) |
| MX (1) | MX2016005915A (enExample) |
| PH (1) | PH12016500840A1 (enExample) |
| RU (1) | RU2016122957A (enExample) |
| WO (1) | WO2015070060A1 (enExample) |
| ZA (1) | ZA201602839B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2679889C2 (ru) | 2013-04-18 | 2019-02-14 | Армо Байосайенсиз, Инк. | Способы применения интерлейкина-10 для лечения заболеваний и расстройств |
| US9823255B2 (en) | 2013-06-17 | 2017-11-21 | Armo Biosciences, Inc. | Method for assessing protein identity and stability |
| WO2015031316A1 (en) | 2013-08-30 | 2015-03-05 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| CN105848674A (zh) | 2013-11-11 | 2016-08-10 | 阿尔莫生物科技股份有限公司 | 将白细胞介素-10用于治疗疾病和病症的方法 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| EP3660050A1 (en) | 2014-03-14 | 2020-06-03 | Novartis AG | Antibody molecules to lag-3 and uses thereof |
| CN106573072A (zh) | 2014-06-02 | 2017-04-19 | 阿尔莫生物科技股份有限公司 | 降低血清胆固醇的方法 |
| KR20170060042A (ko) | 2014-09-13 | 2017-05-31 | 노파르티스 아게 | Alk 억제제의 조합 요법 |
| WO2016060996A2 (en) | 2014-10-14 | 2016-04-21 | Armo Biosciences, Inc. | Interleukin-15 compositions and uses thereof |
| MX2017004983A (es) | 2014-10-22 | 2017-11-13 | Armo Biosciences Inc | Metodos para usar interleucina 10 para tratar enfermedades y trastornos. |
| WO2016126615A1 (en) | 2015-02-03 | 2016-08-11 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| JP7121496B2 (ja) | 2015-05-28 | 2022-08-18 | アルモ・バイオサイエンシーズ・インコーポレイテッド | 癌治療で使用するためのペグ化インターロイキン－１０ |
| US20190307849A1 (en) * | 2015-05-29 | 2019-10-10 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| US10881732B2 (en) | 2015-06-01 | 2021-01-05 | Maine Medical Center Research Institute | Enhancing the therapeutic activity of an immune checkpoint inhibitor |
| SI3334431T1 (sl) | 2015-08-11 | 2020-01-31 | Novartis Ag | 5-bromo-2,6-di-(1h-pirazol-l-il)pyrimidin-4-amin za uporabo v zdravljenju raka |
| JP7053453B2 (ja) * | 2015-08-25 | 2022-04-12 | アルモ・バイオサイエンシーズ・インコーポレイテッド | 疾患及び障害を治療するためのインターロイキン１０の使用方法 |
| KR102220275B1 (ko) | 2015-11-18 | 2021-02-26 | 머크 샤프 앤드 돔 코포레이션 | Pd1 및/또는 lag3 결합제 |
| PT3377534T (pt) | 2015-11-18 | 2025-07-10 | Bristol Myers Squibb Co | Tratamento do cancro do pulmão utilizando uma combinação de um anticorpo anti-pd-1 e de um anticorpo anti-ctla-4 |
| EP3402512A4 (en) | 2016-01-11 | 2019-09-25 | Armo Biosciences, Inc. | INTERLEUKIN-10 IN THE PREPARATION OF ANTIGEN-SPECIFIC CD8 + T CELLS AND METHOD FOR THE USE THEREOF |
| WO2017143115A2 (en) | 2016-02-18 | 2017-08-24 | Maine Medical Center Research Institute | Enhancing the therapeutic activity of an immune checkpoint inhibitor |
| SG11201807421TA (en) | 2016-03-01 | 2018-09-27 | Corcept Therapeutics Inc | The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors |
| KR102182957B1 (ko) * | 2017-02-28 | 2020-11-27 | 진메디신 주식회사 | 종양 특이적 살상 아데노바이러스 및 면역 관문 억제제를 포함하는 항암용 조성물 |
| WO2018184965A1 (en) * | 2017-04-03 | 2018-10-11 | F. Hoffmann-La Roche Ag | Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody |
| GB201714430D0 (en) * | 2017-09-07 | 2017-10-25 | Micol Romain | Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue |
| CN111315398A (zh) * | 2017-11-10 | 2020-06-19 | 阿尔莫生物科技股份有限公司 | 白介素-10与免疫检查点途径抑制剂的组合的组合物和使用方法 |
| RU2020135495A (ru) | 2018-03-28 | 2022-04-29 | Гербалайф Интернэшнл Оф Америка, Инк. | Ацетилирование полисахаридов |
| GB201810058D0 (en) * | 2018-06-19 | 2018-08-08 | Cytovation As | Combination therapy using a peptide |
| US20210347842A1 (en) * | 2018-06-19 | 2021-11-11 | Eli Lilly And Company | Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy |
| WO2020132046A1 (en) | 2018-12-19 | 2020-06-25 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| AU2019406214A1 (en) * | 2018-12-21 | 2021-08-05 | Northwestern University | Use of annexins in preventing and treating muscle membrane injury |
| US12006345B2 (en) | 2019-02-21 | 2024-06-11 | Xencor, Inc. | Untargeted and targeted IL-10 Fc-fusion proteins |
| BR102019007044A2 (pt) | 2019-04-05 | 2021-12-28 | Universidade Federal de Uberlândia | Peptídeos sintéticos com afinidade ao receptor de interleucina-10, composição farmacêutica e uso dos mesmos como imunomuduladores no tratamento de doenças autoimunes, inflamatórias ou alérgicas |
| JP2022537515A (ja) * | 2019-06-10 | 2022-08-26 | アポロミクス インコーポレイテッド（ハンジョウ） | 抗体－インターロイキン融合タンパク質および使用方法 |
| MX2022001975A (es) | 2019-08-16 | 2022-03-11 | Applied Molecular Transport Inc | Composiciones, formulaciones y produccion y purificacion de interleucinas. |
| CN115667290A (zh) | 2020-05-12 | 2023-01-31 | 再生元制药公司 | 新型il10激动剂及其使用方法 |
| US20240190934A1 (en) * | 2022-11-28 | 2024-06-13 | Elixiron Immunotherapeutics (hong Kong) Limited | Engineered interleukin-10 and fusion proteins thereof |
Family Cites Families (133)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1202840A (en) | 1985-06-10 | 1986-04-08 | Jonathan R. Kleinsasser | Combination wet and dry feeder for animals |
| JPS63152393A (ja) | 1986-07-03 | 1988-06-24 | Takeda Chem Ind Ltd | グリコシル誘導体 |
| US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
| US5714585A (en) | 1987-10-26 | 1998-02-03 | Sterling Winthrop, Inc. | Antibodies that are immunoreactive with interleukin-7 |
| US5032396A (en) | 1989-02-17 | 1991-07-16 | Immunex Corporation | IL-7 to stimulate platelet production |
| US6217857B1 (en) | 1989-06-28 | 2001-04-17 | Schering Corporation | Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof |
| US5231012A (en) | 1989-06-28 | 1993-07-27 | Schering Corporation | Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10) |
| US5229115A (en) | 1990-07-26 | 1993-07-20 | Immunex Corporation | Adoptive immunotherapy with interleukin-7 |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| EP0567586B1 (en) | 1991-01-16 | 1995-07-12 | Schering Corporation | Use of interleukin-10 in adoptive immunotherapy of cancer |
| ATE116550T1 (de) | 1991-01-16 | 1995-01-15 | Schering Corp | Behandlung von neoplastischen krankenheiten mit interleukin-10. |
| US5624823A (en) | 1991-11-22 | 1997-04-29 | The General Hospital Corporation | DNA encoding procine interleukin-10 |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| AU6000894A (en) | 1993-02-01 | 1994-08-29 | Michel Goldman | Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10 |
| US5328989A (en) | 1993-03-05 | 1994-07-12 | Schering-Plough | Purification of human interleukin-10 from a cell culture medium |
| US5552303A (en) | 1993-03-08 | 1996-09-03 | Immunex Corporation | DNA encoding epithelium-derived T-cell factor |
| WO1994022473A1 (en) | 1993-04-01 | 1994-10-13 | University Of Washington | Use of interleukin 7 to improve vaccine potency |
| US5665345A (en) | 1993-05-24 | 1997-09-09 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of inhibiting viral replication using IL-10 |
| NZ269663A (en) | 1993-07-26 | 1997-09-22 | Schering Corp | Agonists and antagonists of il-10 |
| GB9317618D0 (en) | 1993-08-24 | 1993-10-06 | Royal Free Hosp School Med | Polymer modifications |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
| PL175343B1 (pl) | 1994-01-20 | 1998-12-31 | Schering Corp | Sposób pozaustrojowego wytwarzania aktywowanych jednojądrzastych komórek krwi obwodowej, kompozycja farmaceutyczna do pozaustrojowego wytwarzania aktywowanych jednojądrzastych komórek krwi obwodowej i kompozycja farmaceutyczna do leczenia nowotworów |
| US5696234A (en) | 1994-08-01 | 1997-12-09 | Schering Corporation | Muteins of mammalian cytokine interleukin-13 |
| US5650234A (en) | 1994-09-09 | 1997-07-22 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US6410008B1 (en) | 1994-12-12 | 2002-06-25 | Beth Israel Hospital Association | Chimeric IL-10 proteins and uses thereof |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5866134A (en) | 1995-03-24 | 1999-02-02 | Schering Corporation | Method for enhancing the antibody response to specific antigens with Interleukin-10 |
| US5770190A (en) | 1995-07-14 | 1998-06-23 | Schering Corporation | Method of treatment of acute leukemia with inteleukin-10 |
| GB2304047A (en) | 1995-08-09 | 1997-03-12 | Univ Manchester | Pharmaceutical compositions containing cytokines |
| US5744451A (en) | 1995-09-12 | 1998-04-28 | Warner-Lambert Company | N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US5759859A (en) | 1996-07-15 | 1998-06-02 | United States Of America As Represented By The Secretary Of The Army | Sensor and method for detecting trace underground energetic materials |
| US5945097A (en) | 1996-09-06 | 1999-08-31 | Schering Corporation | Method for lowering cholesterol levels with interleukin-10 |
| US5989867A (en) | 1996-09-23 | 1999-11-23 | Knappe; Andrea | DNA encoding IL-10-like homologue; related reagents |
| US6660258B1 (en) | 1997-05-09 | 2003-12-09 | Pharma Pacific Pty Ltd | Oromucosal cytokine compositions and uses thereof |
| IL133974A0 (en) | 1997-07-14 | 2001-04-30 | Bolder Biotechnology Inc | Derivatives of growth hormone and related proteins |
| US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
| US6362276B1 (en) | 1998-01-07 | 2002-03-26 | Debio Recherche Pharmaceutique S.A. | Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom |
| US6428985B1 (en) | 1998-12-02 | 2002-08-06 | The Regents Of The University Of Michigan | Immunosuppressive structural definition of IL-10 |
| AU2158000A (en) | 1998-12-22 | 2000-07-12 | Schering Corporation | Treatment of hepatitis c virus infections with interleukin-10 |
| US7666400B2 (en) | 2005-04-06 | 2010-02-23 | Ibc Pharmaceuticals, Inc. | PEGylation by the dock and lock (DNL) technique |
| AU5827000A (en) | 1999-07-16 | 2001-02-05 | Maria Teresa Bejarano | Viral il-10 uses |
| US6989377B2 (en) | 1999-12-21 | 2006-01-24 | Wisconsin Alumni Research Foundation | Treating vitamin D responsive diseases |
| US20030186386A1 (en) | 2000-02-11 | 2003-10-02 | Hansen Christian Karsten | Interleukin 10 |
| AU2001231532A1 (en) | 2000-02-11 | 2001-08-20 | Maxygen Aps | Improved interleukin 10 |
| ES2367891T3 (es) | 2000-09-29 | 2011-11-10 | Schering Corporation | Interleucina-10 pegilada. |
| JP2002142770A (ja) | 2000-11-08 | 2002-05-21 | Dnavec Research Inc | 循環系への遺伝子送達用パラミクソウイルスベクター |
| US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| EP1234583A1 (en) | 2001-02-23 | 2002-08-28 | F. Hoffmann-La Roche Ag | PEG-conjugates of HGF-NK4 |
| AU2002307497A1 (en) | 2001-04-23 | 2002-11-05 | The Regents Of The University Of California | Methods of using interleukin-7 to modulate physiological processes in mammalian pulmonary fibroblasts |
| GB0212648D0 (en) | 2002-05-31 | 2002-07-10 | Immunoclin Lab Ltd | Treatment with cytokines |
| EP1391513A1 (en) | 2002-08-08 | 2004-02-25 | Cytheris | IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof |
| US7611700B2 (en) | 2002-09-09 | 2009-11-03 | Hanall Pharmaceuticals, Co., Ltd. | Protease resistant modified interferon alpha polypeptides |
| AU2003280315A1 (en) | 2002-11-14 | 2004-06-03 | Maxygen, Inc. | Conjugates of interleukin-10 and polymers |
| ES2312820T3 (es) | 2002-11-29 | 2009-03-01 | Maria Grazia Roncarolo | Paramicina e il-10 para el tratamiento de enfermedades autoinmunes. |
| AU2003303222A1 (en) | 2002-12-19 | 2004-07-14 | Universiteit Gent | Mutant proteins showing increased secretion |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| US20040136952A1 (en) | 2002-12-26 | 2004-07-15 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
| EP2949658B1 (en) | 2003-03-03 | 2018-08-08 | Dyax Corp. | Peptides that specifically bind HGF receptor (cMet) and uses thereof |
| EP1613274B1 (en) | 2003-04-15 | 2010-03-03 | GlaxoSmithKline LLC | Human il-18 substitution mutants and their conjugates |
| US7261882B2 (en) | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
| WO2005033307A1 (ja) | 2003-09-30 | 2005-04-14 | Kyowa Hakko Kogyo Co., Ltd. | 新規のリフォールディング方法およびその方法によって得られたタンパク質 |
| ATE457353T1 (de) | 2003-11-28 | 2010-02-15 | Univ Sydney | Virales latentphasen-interleukin-10-(vii-10) und verwendungen davon |
| DK1699822T3 (da) | 2003-12-30 | 2008-08-04 | Merck Patent Gmbh | IL-7-fusionsproteiner med antistofdele, fremstilling deraf og anvendelse deraf |
| US20060078942A1 (en) | 2004-03-10 | 2006-04-13 | Pepgen Corporation | Method of treatment using interferon-tau |
| SG151261A1 (en) | 2004-03-11 | 2009-04-30 | Fresenius Kabi De Gmbh | Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination |
| ES2663810T3 (es) | 2004-08-10 | 2018-04-17 | Kastle Therapeutics, Llc | Métodos para modular los niveles de lipoproteínas y colesterol en humanos |
| US20060046961A1 (en) | 2004-09-02 | 2006-03-02 | Mckay William F | Controlled and directed local delivery of anti-inflammatory compositions |
| CN100334112C (zh) | 2004-10-15 | 2007-08-29 | 上海海欣生物技术有限公司 | 人白细胞介素15与Fc融合蛋白 |
| DE602005020837D1 (de) | 2004-12-09 | 2010-06-02 | Merck Patent Gmbh | Il-7-varianten mit reduzierter immunogenität |
| GB0500643D0 (en) | 2005-01-13 | 2005-02-23 | Renovo Ltd | Medicaments |
| WO2006094530A1 (en) | 2005-03-11 | 2006-09-14 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
| AR052741A1 (es) | 2005-04-08 | 2007-03-28 | Noxxon Pharma Ag | Acidos nucleicos de union a ghrelin |
| EP1901769A2 (en) | 2005-05-02 | 2008-03-26 | Avigen, Inc. | Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease |
| EP2418278A3 (en) * | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| US7749490B2 (en) | 2005-05-31 | 2010-07-06 | The Regents Of The University Of Colorado | Mutant IL-10 |
| CA2655511C (en) | 2005-07-01 | 2017-03-21 | John Schrader | Methods of isolating cells and generating monoclonal antibodies |
| EP1746161A1 (en) | 2005-07-20 | 2007-01-24 | Cytheris | Glycosylated IL-7, preparation and uses |
| WO2007041713A1 (en) | 2005-10-04 | 2007-04-12 | Zymogenetics, Inc. | Production and purification of il-29 |
| US7939056B2 (en) | 2005-11-14 | 2011-05-10 | The Brigham And Women's Hospital, Inc. | Interleukin-10 compositions for the treatment of adenocarcinomas |
| WO2007087576A2 (en) | 2006-01-24 | 2007-08-02 | The Uab Research Foundation | Compositions and methods for the identification and treatment of immune-mediated inflammatory diseases |
| US7662965B2 (en) * | 2006-01-26 | 2010-02-16 | Cornerstone Therapeutics, Inc. | Anabaseine derivatives, pharmaceutical compositions and method of use thereof |
| EP2066336B1 (en) * | 2006-09-28 | 2012-09-19 | Merck Sharp & Dohme Corp. | Use of pegylated il-10 to treat cancer |
| JP2010506166A (ja) | 2006-10-05 | 2010-02-25 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | デング熱の診断及び治療 |
| US8247370B2 (en) | 2006-12-04 | 2012-08-21 | Promedior, Inc. | Conjoint therapy for treating fibrotic diseases |
| AU2008206077A1 (en) | 2007-01-19 | 2008-07-24 | Kai Pharmaceuticals, Inc. | Modifications of peptide compositions to increase stability and delivery efficiency |
| WO2009014708A2 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| US8937153B2 (en) | 2007-07-31 | 2015-01-20 | Affibody Ab | Compositions, methods and uses |
| WO2009036568A1 (en) | 2007-09-19 | 2009-03-26 | University Health Network | Methods and compositions for treating tumors and viral infections |
| CA2702494A1 (en) | 2007-10-19 | 2009-04-23 | The Regents Of The University Of California | Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss |
| CA2706700A1 (en) | 2007-11-08 | 2009-05-14 | Cytimmune Sciences, Inc. | Compositions and methods for generating antibodies |
| GB0724231D0 (en) | 2007-12-12 | 2008-01-30 | Renono Ltd | Methods for inhibiting scarring |
| KR20110013423A (ko) | 2008-05-29 | 2011-02-09 | 브리스톨-마이어스 스큅 컴퍼니 | 보조자극 경로의 조절에 대한 환자 반응을 예측하는 방법 |
| WO2010022227A1 (en) | 2008-08-20 | 2010-02-25 | Schering Corporation | Methods for monitoring il-10 therapy |
| US8927694B2 (en) | 2008-11-18 | 2015-01-06 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
| ES2655364T3 (es) | 2008-12-17 | 2018-02-19 | Merck Sharp & Dohme Corp. | Producción de IL-10 mono- y dipegilada y sus usos |
| EP3381937A3 (en) * | 2009-08-13 | 2018-10-31 | The Johns Hopkins University | Methods of modulating immune function |
| CA2777053A1 (en) | 2009-10-06 | 2011-04-14 | The Board Of Trustees Of The University Of Illinois | Human single-chain t cell receptors |
| WO2011045704A1 (en) * | 2009-10-12 | 2011-04-21 | Pfizer Inc. | Cancer treatment |
| RU2607374C2 (ru) | 2009-10-30 | 2017-01-10 | Новозаймс Байофарма Дк А/С | Варианты альбумина |
| MX343228B (es) | 2009-11-30 | 2016-10-26 | Biotest Ag | Anticuerpos anti-il-10humanizados para el tratamiento de lupus sistémico eritematoso. |
| JP6066732B2 (ja) * | 2010-03-05 | 2017-01-25 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 標的免疫調節抗体および融合タンパク質に基づく組成物および方法 |
| US9170262B2 (en) | 2010-06-16 | 2015-10-27 | Abbvie, Inc. | Comparison of protein samples |
| JP2013532153A (ja) | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体 |
| WO2012004384A2 (en) | 2010-07-09 | 2012-01-12 | Affibody Ab | Polypeptides |
| US8759617B2 (en) | 2010-09-21 | 2014-06-24 | National Institute Of Agrobiological Sciences | Method for extraction and purification of recombinant proteins from transgenic plants |
| ES2563091T3 (es) | 2010-09-28 | 2016-03-10 | Amylin Pharmaceuticals, Llc | Polipéptidos modificados genéticamente que tienen duración de acción potenciada |
| PT2621519T (pt) | 2010-09-28 | 2017-10-04 | Aegerion Pharmaceuticals Inc | Polipéptido de fusão de leptina-abd com duração de ação melhorada |
| US8895536B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating chronic inflammation and inflammatory diseases |
| CN110200997A (zh) | 2011-03-23 | 2019-09-06 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的方法和组合物 |
| CN102145178B (zh) | 2011-04-15 | 2012-09-26 | 北京凯因科技股份有限公司 | Peg化白介素15 |
| EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| US20140242081A1 (en) * | 2011-07-18 | 2014-08-28 | Micromet Ag | Dosing regimens for treatment of cea-expressing cancers |
| EP2768856A4 (en) | 2011-10-18 | 2015-05-27 | Prolynx Llc | PEG CONJUGATES OF EXENATIDE |
| US10391126B2 (en) | 2011-11-18 | 2019-08-27 | Board Of Regents, The University Of Texas System | CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA |
| KR20140125803A (ko) | 2012-01-26 | 2014-10-29 | 암젠 인크 | 성장 분화 인자 15(gdf-15) 폴리펩타이드들 |
| CN104245722A (zh) | 2012-02-29 | 2014-12-24 | Ambrx公司 | 白细胞介素-10多肽结合物和其用途 |
| US20150118244A1 (en) | 2012-05-10 | 2015-04-30 | Bristol-Myers Squibb Company | Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients |
| WO2014110867A1 (zh) | 2013-01-17 | 2014-07-24 | 厦门赛诺邦格生物科技有限公司 | 一种单一官能化的支化聚乙二醇及其修饰的生物相关物质 |
| RU2679889C2 (ru) | 2013-04-18 | 2019-02-14 | Армо Байосайенсиз, Инк. | Способы применения интерлейкина-10 для лечения заболеваний и расстройств |
| US20160068583A1 (en) | 2013-04-24 | 2016-03-10 | Armo Biosciences, Inc. | Interleukin-10 Compositions and Uses Thereof |
| US9823255B2 (en) | 2013-06-17 | 2017-11-21 | Armo Biosciences, Inc. | Method for assessing protein identity and stability |
| WO2015031316A1 (en) | 2013-08-30 | 2015-03-05 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| CN105848674A (zh) | 2013-11-11 | 2016-08-10 | 阿尔莫生物科技股份有限公司 | 将白细胞介素-10用于治疗疾病和病症的方法 |
| US20160375101A1 (en) | 2014-01-15 | 2016-12-29 | Armo Biosciences, Inc. | Methods of Using Interleukin-10 for Treating Diseases and Disorders |
| ES2963718T3 (es) | 2014-01-21 | 2024-04-01 | Novartis Ag | Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras |
| MA39711A (fr) | 2014-04-03 | 2015-10-08 | Nektar Therapeutics | Conjugués d'une fraction d'il-15 et d'un polymère |
| CN106573072A (zh) | 2014-06-02 | 2017-04-19 | 阿尔莫生物科技股份有限公司 | 降低血清胆固醇的方法 |
| CN107405384A (zh) | 2015-03-11 | 2017-11-28 | 尼克塔治疗公司 | Il‑7部分与聚合物的缀合物 |
| JP7121496B2 (ja) | 2015-05-28 | 2022-08-18 | アルモ・バイオサイエンシーズ・インコーポレイテッド | 癌治療で使用するためのペグ化インターロイキン－１０ |
-
2014
- 2014-11-07 CN CN201480068159.5A patent/CN105848674A/zh active Pending
- 2014-11-07 JP JP2016528896A patent/JP6660297B2/ja active Active
- 2014-11-07 RU RU2016122957A patent/RU2016122957A/ru unknown
- 2014-11-07 CA CA2928710A patent/CA2928710A1/en not_active Abandoned
- 2014-11-07 US US15/031,651 patent/US11413332B2/en active Active
- 2014-11-07 ES ES14860137T patent/ES2862139T3/es active Active
- 2014-11-07 MX MX2016005915A patent/MX2016005915A/es unknown
- 2014-11-07 BR BR112016010166A patent/BR112016010166A2/pt not_active IP Right Cessation
- 2014-11-07 AU AU2014346537A patent/AU2014346537A1/en not_active Abandoned
- 2014-11-07 EP EP14860137.0A patent/EP3068425B1/en active Active
- 2014-11-07 CN CN202510416932.2A patent/CN120242030A/zh active Pending
- 2014-11-07 KR KR1020167015158A patent/KR20160079114A/ko not_active Withdrawn
- 2014-11-07 WO PCT/US2014/064620 patent/WO2015070060A1/en not_active Ceased
-
2016
- 2016-04-25 ZA ZA2016/02839A patent/ZA201602839B/en unknown
- 2016-04-25 IL IL245303A patent/IL245303A0/en unknown
- 2016-05-05 PH PH12016500840A patent/PH12016500840A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2016122957A (ru) | 2017-12-19 |
| JP2016537340A (ja) | 2016-12-01 |
| MX2016005915A (es) | 2016-12-16 |
| KR20160079114A (ko) | 2016-07-05 |
| ZA201602839B (en) | 2017-09-27 |
| EP3068425A4 (en) | 2017-05-17 |
| CN105848674A (zh) | 2016-08-10 |
| AU2014346537A1 (en) | 2016-05-19 |
| US20160243196A1 (en) | 2016-08-25 |
| US11413332B2 (en) | 2022-08-16 |
| PH12016500840A1 (en) | 2016-07-11 |
| CN120242030A (zh) | 2025-07-04 |
| IL245303A0 (en) | 2016-06-30 |
| EP3068425B1 (en) | 2021-01-27 |
| WO2015070060A1 (en) | 2015-05-14 |
| JP6660297B2 (ja) | 2020-03-11 |
| EP3068425A1 (en) | 2016-09-21 |
| ES2862139T3 (es) | 2021-10-07 |
| CA2928710A1 (en) | 2015-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016010166A2 (pt) | métodos para usar interleucina-10 para tratar doenças e distúrbios | |
| JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
| BR112015026122A2 (pt) | métodos para usar interleucina-10 para tratar doenças e desordens | |
| IL283432A (en) | Compositions, methods and systems for the treatment of cutaneous disorders | |
| CY1121893T1 (el) | Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων | |
| EA201591754A1 (ru) | Человеческие антитела к na1.7 | |
| MX2018006578A (es) | Formulaciones farmaceuticas topicas para tratar afecciones inflamatorias. | |
| MX2015009058A (es) | Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias. | |
| MX2024010175A (es) | Moleculas de anticuerpo contra april y usos de las mismas. | |
| MX392779B (es) | Anticuerpos anti-cd27 | |
| MX384490B (es) | Agentes que inducen apoptosis para el tratamiento de cancer y enfermedades inmunitarias y autoinmunitarias. | |
| MX382466B (es) | Partículas inmunomodificadoras para el tratamiento de la inflamación. | |
| EA201790377A1 (ru) | Антитела к глюкагону и их применения | |
| DOP2015000246A (es) | Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares | |
| ES2765949T8 (es) | Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer | |
| MX377340B (es) | Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares. | |
| EA202090632A1 (ru) | Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов | |
| BR112017018964A2 (pt) | uso de plinabulin e métodos para tratar tumor cerebral | |
| EA201890747A1 (ru) | Способы лечения воспалительных заболеваний | |
| EA201691314A1 (ru) | Терапевтические способы и композиции | |
| NI201500150A (es) | TRATAMIENTO DE CÁNCER CON DIHIDROPIRAZINO-PIRAZINAS×Se proporcionan en la presente método | |
| MX386055B (es) | Uso de medicamentos para disminuir la evolución de la enfermedad de parkinson. | |
| BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
| HK1226308A1 (zh) | 使用白细胞介素-10治疗疾病和病症的方法 | |
| NI201600070A (es) | Inhibidores tetracíclicos de autotaxina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2603 DE 24-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |